Androgenetic alopecia is a common form of hair loss caused by genetic and hormonal factors, primarily affecting men and women as they age. As per Emad Bahashwan et al., 2024, alopecia areata has a global prevalence of around 2%. According to the androgenetic alopecia pipeline analysis by Expert Market Research, the growing focus on novel therapies, such as JAK inhibitors, stem cell treatments, and topical anti-androgens, is driving innovation. Increasing awareness, psychological impact, and rising prevalence are expected to boost market growth in the coming years.
Major companies involved in the androgenetic alopecia pipeline analysis include Veradermics, Inc., Pelage Pharmaceuticals, Inc., and others.
Leading drugs currently in the pipeline include VDPHL01, PP405, AH-001, and others.
Strong pipeline growth for androgenetic alopecia drugs is driven by increasing R&D investments, rising demand for targeted therapies, and advancements in regenerative medicine, including stem cell-based and gene therapies.
The Androgenetic Alopecia Pipeline Analysis Report by Expert Market Research gives comprehensive insights into androgenetic alopecia therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for androgenetic alopecia. The androgenetic alopecia report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The androgenetic alopecia pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with androgenetic alopecia treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to androgenetic alopecia.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Androgenetic alopecia, commonly known as pattern hair loss, is a genetic condition that causes progressive hair thinning due to the miniaturization of hair follicles. It occurs when dihydrotestosterone (DHT), a hormone derived from testosterone, shortens the hair growth cycle and shrinks follicles, leading to finer hair and eventual hair loss.
Androgenetic alopecia treatments include FDA-approved options such as topical minoxidil, oral finasteride, and low-level laser therapy. These therapies help by either stimulating hair follicles or blocking DHT, thus slowing hair loss and promoting regrowth. In March 2024, a Phase III clinical trial evaluating low-dose oral minoxidil for androgenetic alopecia demonstrated promising results in hair density improvement with fewer cardiovascular side effects, marking a significant advancement in the treatment pipeline.
According to Emad Bahashwan et al. (2024), the global prevalence of alopecia areata is approximately 2%, often linked with significant psychological impacts. As per Lorena Pozo-Pérez et al. (2024), androgenetic alopecia (AGA) affects up to 80% of Caucasian men and 30-50% of individuals under 50 years, with similar rates in older women. In China, Changpei Lu et al. (2024) reported AGA prevalence at 21.3% in males and 6.0% in females. The increasing incidence of AGA continues to fuel demand and innovation in drug development pipelines.
This section of the report covers the analysis of androgenetic alopecia drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
By Drug Class
The androgenetic alopecia pipeline analysis report covers 50+ drug analyses based on drug classes:
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III accounts for nearly 40% of the studies, covering a major share of the total androgenetic alopecia clinical trials. This reflects strong advancements toward late-stage development. Phase II holds 30%, showcasing significant research activity. Phase I contributes 15%, while Phase IV represents 9%. This well-distributed pipeline signals robust innovation, likely to enhance treatment options and drive market growth.
The drug molecule categories covered under the androgenetic alopecia pipeline analysis include small molecules, biologics, cell-based therapies, gene therapies, and nutraceuticals. The androgenetic alopecia report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for androgenetic alopecia. Topical therapies are gaining momentum in the androgenetic alopecia drug pipeline due to their non-hormonal mechanisms and improved safety profiles. For instance, ET-02, a topical formulation by Eirion Therapeutics, demonstrated a six-fold increase in non-vellus hair count compared to placebo in its first-in-human trial. Additionally, the therapy showed significant improvement in hair width, indicating its potential as a well-tolerated and effective alternative to current standards like minoxidil.
The EMR report for the androgenetic alopecia pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed androgenetic alopecia therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in androgenetic alopecia clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for androgenetic alopecia. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of androgenetic alopecia drug candidates.
VDPHL01, developed by Veradermics, Inc., is a first-in-human, investigational, proprietary oral treatment being developed for pattern hair loss. This non-hormonal drug is designed to minimize androgen-driven follicular shrinkage without interfering with the body's hormonal balance. Unlike finasteride, which can cause side effects, VDPHL01 aims to offer a safer, more targeted alternative. Currently in Phase 3 trials, the study is evaluating its safety and efficacy in men with androgenetic alopecia, with hopes of establishing it as a breakthrough therapy in hair loss treatment.
PP405, developed by Pelage Pharmaceuticals, Inc., is a topical 0.05% gel formulated to reactivate dormant hair follicle stem cells, aiming to restore natural hair growth in individuals with androgenetic alopecia (AGA). This small-molecule therapy is currently undergoing a Phase 2a clinical trial, focusing on evaluating its safety, pharmacokinetics, and efficacy. PP405 is being positioned as a noninvasive, regenerative solution for AGA, potentially transforming current treatment approaches.
AH-001, developed by AnHorn Medicines Co. Ltd., is an innovative topical protein degrader currently undergoing Phase 1 clinical evaluation. It is specifically engineered to selectively degrade the Androgen Receptor (AR), a key factor in androgenetic alopecia. AH-001 is offering a novel therapeutic approach by eliminating the disease-causing protein rather than just inhibiting it. This ongoing study is assessing the safety, tolerability, and pharmacokinetics of single and multiple ascending doses in healthy volunteers and males with AGA, potentially establishing AH-001 as a superior alternative to current treatments.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Androgenetic Alopecia Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for androgenetic alopecia. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into androgenetic alopecia collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share